Compare HRTG & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTG | OMER |
|---|---|---|
| Founded | 2012 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 898.0M | 894.8M |
| IPO Year | 2014 | 2009 |
| Metric | HRTG | OMER |
|---|---|---|
| Price | $24.63 | $11.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $32.50 | $32.50 |
| AVG Volume (30 Days) | 242.0K | ★ 1.4M |
| Earning Date | 03-10-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.61 | N/A |
| EPS | ★ 4.83 | N/A |
| Revenue | ★ $842,277,000.00 | N/A |
| Revenue This Year | $5.45 | N/A |
| Revenue Next Year | $7.27 | N/A |
| P/E Ratio | $5.14 | ★ N/A |
| Revenue Growth | ★ 6.12 | N/A |
| 52 Week Low | $9.89 | $2.95 |
| 52 Week High | $31.98 | $17.65 |
| Indicator | HRTG | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 37.01 | 50.35 |
| Support Level | $24.23 | $11.00 |
| Resistance Level | $25.87 | $11.46 |
| Average True Range (ATR) | 1.02 | 0.60 |
| MACD | -0.07 | -0.00 |
| Stochastic Oscillator | 21.71 | 60.45 |
Heritage Insurance Holdings Inc is a regional property and casualty insurance company that offers a variety of personal and commercial insurance products. Through its subsidiaries, Heritage Property & Casualty Insurance, Narragansett Bay Insurance, and Zephyr Insurance, the company issues personal residential property insurance in various states in the United States. It also offers commercial residential insurance predominantly for its Florida properties. Heritage Insurance manages insurance underwriting, customer services, actuarial analysis, distribution, and claims processing internally. Company operates in Alabama, California, Connecticut, Delaware, Florida, Georgia, Hawaii, Maryland, Massachusetts, Mississippi, New Jersey, New York, North Carolina, Rhode Island, South Carolina.
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.